Andrew Witty

Andrew Witty is not a central actor in the Valeant fraud, but he matters because he helped define the moral weather around it. Born in 1964 in the United Kingdom, he came of age inside the pharmaceutical establishment rather than outside it, and that distinction is important. Witty spent his career learning the industry from the inside: how patents create value, how pricing supports research, how regulation and public scrutiny can make even legitimate business feel perpetually under siege. He rose through GlaxoSmithKline and later became its chief executive, a role that required him to defend a company’s profits while also defending its social license to operate. That dual burden shaped the kind of executive he became—pragmatic, institution-minded, and unusually attuned to the danger of appearing greedy in a sector already suspected of exploitation.

Witty’s significance in the Valeant story lies in how he functioned as an insider critic. He did not expose accounting fraud or engineer a collapse; instead, he helped frame the question of legitimacy. Valeant’s model depended on acquisitions, aggressive price increases, and a relentless financial logic that treated medicine less as a public good than as a monetizable asset. Witty represented a different strain of pharmaceutical capitalism: one that still pursued profit, but insisted that profit had to survive public scrutiny. That position is revealing because it is not anti-capitalist at all. It is the voice of someone trying to preserve the industry by warning that some methods are so extractive they threaten the whole system’s moral credibility.

This is where the psychological tension becomes visible. Publicly, Witty often appeared as a sober reformer, a steward of a complex industry forced to answer to patients, governments, and investors all at once. Privately, however, he remained a corporate executive with the usual incentives: protect margins, reassure shareholders, preserve competitive advantage, and present hard commercial choices as responsible governance. The contradiction is not that he was disingenuous in a simple sense, but that he was trying to occupy two moral worlds at once. He wanted the legitimacy of public-minded stewardship without abandoning the imperatives of corporate success.

That tension gave his criticism of Valeant additional force. When an insider condemns a peer for predatory pricing, the rebuke lands differently than when it comes from politicians or activists. It tells the public that the line had been crossed not merely by outsiders’ standards but by the industry’s own internal code. In that sense, Witty helped expose the deeper scandal: not just that Valeant’s tactics harmed patients and distorted markets, but that they pushed the pharmaceutical sector toward a model in which legitimacy itself became a financial afterthought.

The cost was broader than one company’s fall. Patients faced higher prices and reduced trust in the motives of drug makers. Investors learned how quickly a ruthlessly efficient business story can curdle into a reputational crisis. And figures like Witty were left with a harder task: defending an industry whose public image had been damaged by executives who mistook extraction for strategy. His role in the Valeant era is therefore less that of a hero than a witness with stakes of his own—a man trying to hold the line between commerce and credibility before the line disappeared altogether.